MX359403B - Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa. - Google Patents
Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa.Info
- Publication number
- MX359403B MX359403B MX2015001732A MX2015001732A MX359403B MX 359403 B MX359403 B MX 359403B MX 2015001732 A MX2015001732 A MX 2015001732A MX 2015001732 A MX2015001732 A MX 2015001732A MX 359403 B MX359403 B MX 359403B
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitor
- optionally
- pi3k
- raf
- egfr
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Una combinación farmacéutica, la cual comprende: (a) un inhibidor de B-Raf, (b) un inhibidor del receptor del factor de crecimiento epidérmico (EGFR) y, opcionalmente, (c) un inhibidor de PI3K; los usos de esta combinación en el tratamiento de enfermedades proliferativas; y los métodos para el tratamiento de un sujeto que padezca de una enfermedad proliferativa, los cuales comprenden administrar una cantidad terapéuticamente efectiva de esta combinación.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261680473P | 2012-08-07 | 2012-08-07 | |
PCT/US2013/053619 WO2014025688A1 (en) | 2012-08-07 | 2013-08-05 | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015001732A MX2015001732A (es) | 2015-06-03 |
MX359403B true MX359403B (es) | 2018-09-26 |
Family
ID=48980368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015001732A MX359403B (es) | 2012-08-07 | 2013-08-05 | Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr, y opcionalmente un inhibidor de pi3k-alfa. |
Country Status (39)
Country | Link |
---|---|
US (1) | US9474754B2 (es) |
EP (2) | EP3574904A1 (es) |
JP (3) | JP6342396B2 (es) |
KR (1) | KR102112885B1 (es) |
CN (1) | CN104519887B (es) |
AR (1) | AR092045A1 (es) |
AU (1) | AU2013299841B8 (es) |
CA (1) | CA2879548C (es) |
CL (1) | CL2015000294A1 (es) |
CO (1) | CO7200273A2 (es) |
CY (1) | CY1122143T1 (es) |
DK (1) | DK2882440T3 (es) |
EA (1) | EA028420B1 (es) |
EC (1) | ECSP15008695A (es) |
ES (1) | ES2717911T3 (es) |
GT (1) | GT201500025A (es) |
HK (2) | HK1204976A1 (es) |
HR (1) | HRP20190537T1 (es) |
HU (1) | HUE042877T2 (es) |
IL (1) | IL236934B (es) |
IN (1) | IN2015DN00450A (es) |
JO (1) | JOP20130236B1 (es) |
LT (1) | LT2882440T (es) |
MA (1) | MA37829A1 (es) |
MX (1) | MX359403B (es) |
MY (1) | MY176031A (es) |
NZ (1) | NZ703940A (es) |
PE (2) | PE20191655A1 (es) |
PH (1) | PH12015500246A1 (es) |
PL (1) | PL2882440T3 (es) |
PT (1) | PT2882440T (es) |
RS (1) | RS58734B1 (es) |
SG (1) | SG11201500321YA (es) |
SI (1) | SI2882440T1 (es) |
TN (1) | TN2015000027A1 (es) |
TR (1) | TR201904980T4 (es) |
TW (1) | TWI607754B (es) |
UA (1) | UA115786C2 (es) |
WO (1) | WO2014025688A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ703940A (en) * | 2012-08-07 | 2018-04-27 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
CN105209073A (zh) | 2013-03-21 | 2015-12-30 | 诺华股份有限公司 | 包含B-Raf抑制剂和第二抑制剂的组合疗法 |
WO2015145388A2 (en) * | 2014-03-27 | 2015-10-01 | Novartis Ag | Methods of treating colorectal cancers harboring upstream wnt pathway mutations |
JP6704861B2 (ja) * | 2014-06-16 | 2020-06-03 | ワールドワイド・イノベイティブ・ネットワークWorldwide Innovative Network | 癌処置のための個別化三剤治療を選択するための方法 |
WO2016193955A1 (en) * | 2015-06-04 | 2016-12-08 | Giorgio Stassi | Combinations of kinase inhibitors for treating colorectal cancer |
JP2018525402A (ja) * | 2015-08-28 | 2018-09-06 | ノバルティス アーゲー | Pi3k阻害剤のアルペリシブおよびb−raf阻害剤のダブラフェニブを含む組合せ医薬、がんの治療または予防におけるそのような組合せの使用 |
EP3380097A2 (en) * | 2015-08-28 | 2018-10-03 | Novartis AG | Pharmaceutical combination comprising (a) the alpha-isoform specific pi3k inhibitor alpelisib (byl719) and (b) an akt inhibitor, preferably mk-2206, afuresertib or uprosertib, and the use thereof in the treatment/prevention of cancer |
WO2017066664A1 (en) * | 2015-10-16 | 2017-04-20 | Millennium Pharmaceuticals, Inc. | Combination therapy including a raf inhibitor for the treatment of colorectal cancer |
SG11201810793XA (en) * | 2016-06-03 | 2018-12-28 | Giordano Caponigro | Pharmaceutical combinations |
CN109715163B (zh) * | 2016-09-19 | 2022-11-22 | 诺华股份有限公司 | 包含raf抑制剂和erk抑制剂的治疗组合 |
CA3069564A1 (en) * | 2017-08-03 | 2019-02-07 | Novartis Ag | Therapeutic combination of a third-generation egfr tyrosine kinase inhibitor and a raf inhibitor |
CN113490668A (zh) | 2018-10-05 | 2021-10-08 | 安娜普尔纳生物股份有限公司 | 用于治疗与apj受体活性有关的疾病的化合物和组合物 |
TW202043225A (zh) * | 2019-01-25 | 2020-12-01 | 英屬開曼群島商百濟神州有限公司 | B-raf激酶二聚體抑制劑之穩定固體分散體、製備方法及其用途 |
WO2020164997A1 (en) * | 2019-02-12 | 2020-08-20 | Bayer Aktiengesellschaft | Combination of pi3k-inhibitors |
WO2023145530A1 (ja) * | 2022-01-27 | 2023-08-03 | 国立大学法人東北大学 | 癌治療剤 |
WO2023230554A1 (en) | 2022-05-25 | 2023-11-30 | Pfizer Inc. | Combination of a braf inhibitor, an egfr inhibitor, and a pd-1 antagonist for the treatment of braf v600e-mutant, msi-h/dmmr colorectal cancer |
WO2024073364A1 (en) * | 2022-09-26 | 2024-04-04 | Beigene, Ltd. | Combinations of a b-raf inhibitor, and an anti-egfr antibody for the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4128089A (en) | 1988-09-15 | 1990-03-22 | Rorer International (Overseas) Inc. | Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
EP2139484B9 (en) | 2007-04-10 | 2014-06-11 | Exelixis, Inc. | Methods of treating cancer using pyridopyrimidinone inhibitors of pi3k alpha |
UA104147C2 (uk) | 2008-09-10 | 2014-01-10 | Новартис Аг | Похідна піролідиндикарбонової кислоти та її застосування у лікуванні проліферативних захворювань |
WO2011028540A1 (en) | 2009-08-24 | 2011-03-10 | Genentech, Inc. | Determining sensitivity of cells to b-raf inhibitor treatment by detecting kras mutation and rtk expression levels |
JO3002B1 (ar) * | 2009-08-28 | 2016-09-05 | Irm Llc | مركبات و تركيبات كمثبطات كيناز بروتين |
MX2012004259A (es) * | 2009-10-12 | 2012-05-29 | Glaxosmithkline Llc | Combinacion. |
US20120045433A1 (en) | 2010-08-17 | 2012-02-23 | Kapil Dhingra | Combination therapy |
BR112013009624A2 (pt) * | 2010-11-08 | 2016-07-12 | Novartis Ag | uso de derivados de 2-carboxamida cicloamino ureia no tratamento de doenças dependemtes de egfr pu doenças que tenham adquirido resistência a agentes que tenham como alvo membros da família egfr |
AU2012335665A1 (en) | 2011-11-10 | 2014-07-03 | Memorial Sloan-Kettering Cancer Center | Treatment of ovarian cancer with 2-amino-4H-naphtho[1,2-B]pyran-3-carbonitriles |
CA2855243C (en) * | 2011-11-11 | 2020-04-14 | Novartis Ag | Method of treating a proliferative disease |
NZ703940A (en) * | 2012-08-07 | 2018-04-27 | Novartis Ag | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor |
-
2013
- 2013-08-05 NZ NZ703940A patent/NZ703940A/en unknown
- 2013-08-05 DK DK13748243.6T patent/DK2882440T3/da active
- 2013-08-05 TR TR2019/04980T patent/TR201904980T4/tr unknown
- 2013-08-05 EA EA201590332A patent/EA028420B1/ru not_active IP Right Cessation
- 2013-08-05 US US14/419,256 patent/US9474754B2/en active Active
- 2013-08-05 PE PE2019001539A patent/PE20191655A1/es unknown
- 2013-08-05 PE PE2015000130A patent/PE20150673A1/es not_active Application Discontinuation
- 2013-08-05 RS RS20190351A patent/RS58734B1/sr unknown
- 2013-08-05 AR ARP130102776A patent/AR092045A1/es not_active Application Discontinuation
- 2013-08-05 MY MYPI2015000102A patent/MY176031A/en unknown
- 2013-08-05 EP EP19159506.5A patent/EP3574904A1/en active Pending
- 2013-08-05 EP EP13748243.6A patent/EP2882440B1/en active Active
- 2013-08-05 PT PT13748243T patent/PT2882440T/pt unknown
- 2013-08-05 HU HUE13748243A patent/HUE042877T2/hu unknown
- 2013-08-05 JP JP2015526606A patent/JP6342396B2/ja active Active
- 2013-08-05 KR KR1020157002982A patent/KR102112885B1/ko active IP Right Grant
- 2013-08-05 CN CN201380042229.5A patent/CN104519887B/zh active Active
- 2013-08-05 SG SG11201500321YA patent/SG11201500321YA/en unknown
- 2013-08-05 IN IN450DEN2015 patent/IN2015DN00450A/en unknown
- 2013-08-05 CA CA2879548A patent/CA2879548C/en active Active
- 2013-08-05 ES ES13748243T patent/ES2717911T3/es active Active
- 2013-08-05 UA UAA201500424A patent/UA115786C2/uk unknown
- 2013-08-05 PL PL13748243T patent/PL2882440T3/pl unknown
- 2013-08-05 WO PCT/US2013/053619 patent/WO2014025688A1/en active Application Filing
- 2013-08-05 LT LTEP13748243.6T patent/LT2882440T/lt unknown
- 2013-08-05 SI SI201331387T patent/SI2882440T1/sl unknown
- 2013-08-05 AU AU2013299841A patent/AU2013299841B8/en active Active
- 2013-08-05 MX MX2015001732A patent/MX359403B/es active IP Right Grant
- 2013-08-06 TW TW102128165A patent/TWI607754B/zh active
- 2013-08-06 JO JOP/2013/0236A patent/JOP20130236B1/ar active
-
2015
- 2015-01-19 TN TNP2015000027A patent/TN2015000027A1/fr unknown
- 2015-01-26 IL IL236934A patent/IL236934B/en active IP Right Grant
- 2015-02-04 MA MA37829A patent/MA37829A1/fr unknown
- 2015-02-04 PH PH12015500246A patent/PH12015500246A1/en unknown
- 2015-02-06 CO CO15024921A patent/CO7200273A2/es unknown
- 2015-02-06 CL CL2015000294A patent/CL2015000294A1/es unknown
- 2015-02-06 GT GT201500025A patent/GT201500025A/es unknown
- 2015-03-06 EC ECIEPI20158695A patent/ECSP15008695A/es unknown
- 2015-06-18 HK HK15105815.5A patent/HK1204976A1/xx unknown
- 2015-11-03 HK HK15110834.2A patent/HK1211831A1/xx unknown
-
2018
- 2018-02-09 JP JP2018022248A patent/JP6595024B2/ja active Active
-
2019
- 2019-03-19 HR HRP20190537TT patent/HRP20190537T1/hr unknown
- 2019-04-30 CY CY20191100461T patent/CY1122143T1/el unknown
- 2019-09-25 JP JP2019174353A patent/JP6974669B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015500246A1 (en) | Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor | |
MX360045B (es) | Combinaciones farmacéuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf. | |
MX2020004023A (es) | Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia. | |
MX2016008362A (es) | Combinaciones farmaceuticas. | |
AU2011328009A8 (en) | Compounds and methods for treating pain | |
MX2014010590A (es) | Terapia de combinacion para trastornos proliferativos. | |
MX2020010412A (es) | Inhibidores de tirosina quinasa de bruton. | |
MX2021010672A (es) | Uso de un anticuerpo que tiene la capacidad para ligarse a clnd6 en el tratamiento o prevención de cáncer. | |
EA201500314A1 (ru) | Лекарственные формы энзалутамида | |
MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
CA3019531A1 (en) | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer | |
MX360189B (es) | Terapia de combinacion para el tratamiento de glioblastoma. | |
MX2019001977A (es) | Metodos y composiciones para tratar esclerosis multiple y trastornos relacionados. | |
PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
PH12015501002A1 (en) | Treatment of cancer with pomalidomide in a renally impaired subject | |
UA115250C2 (uk) | Фармацевтичні комбінації | |
EA201491836A1 (ru) | Способы лечения рака с использованием ингибитора pi3k и ингибитора mek | |
MX2017001983A (es) | Agentes de union a proteina r-espondina 1 (rspo1) y usos de los mismos. | |
NZ745950A (en) | Methods and compositions for treating multiple sclerosis and related disorders | |
UA86338U (ru) | Способ лечения беременных с гестационным диабетом | |
UA88769U (uk) | Спосіб профілактики та лікування доброякісних дисплазій молочних залоз у жінок з ранніми втратами вагітності |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |